Lynn Seely - Myovant Sciences Principal Executive Officer, Director
| MYOVDelisted Stock | USD 26.98 0.01 0.04% |
Director
Dr. Lynn Seely, M.D. is a Principal Executive Officer, Director of the Company. Dr. Seely has served as a member of the Board since May 2016 and as our Principal Executive Officer and the President and Chief Executive Officer of Myovant Sciences, Inc., our wholly owned subsidiary, since May 2016. From March 2005 to October 2015, Dr. Seely served as Chief Medical Officer of Medivation, Inc., a biopharmaceutical company, where she served on the Executive Committee and led the development of XTANDI for the treatment of metastatic castrationresistant prostate cancer from INDenabling studies through to NDA approval and postapproval clinical studies. Dr. Seely was responsible for building the clinical organization at Medivation, Inc., as well as the regulatory, quality, project management, medical affairs and biologics manufacturing functions. Dr. Seely previously served as Vice President of Clinical Development at Anesiva, Inc., a biopharmaceutical company, and at Cytyc Health Corporationrationration, a medical device company. In addition, she currently serves as a director of Blueprint Medicines Corporationrationration, a biotechnology company since 2016.
| Age | 59 |
| Tenure | 8 years |
| Professional Marks | Ph.D |
| Phone | 44 20 7400 3351 |
| Web | https://myovant.com |
Lynn Seely Latest Insider Activity
Tracking and analyzing the buying and selling activities of Lynn Seely against Myovant Sciences stock is an integral part of due diligence when investing in Myovant Sciences. Lynn Seely insider activity provides valuable insight into whether Myovant Sciences is net buyers or sellers over its current business cycle. Note, Myovant Sciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Myovant Sciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Lynn Seely over six months ago Acquisition by Lynn Seely of 2600 shares of Blueprint Medicines subject to Rule 16b-3 |
Myovant Sciences Management Efficiency
The company has return on total asset (ROA) of (0.1822) % which means that it has lost $0.1822 on every $100 spent on assets. This is way below average. Myovant Sciences' management efficiency ratios could be used to measure how well Myovant Sciences manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 358.7 M in liabilities with Debt to Equity (D/E) ratio of 138.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Myovant Sciences has a current ratio of 1.79, which is within standard range for the sector. Debt can assist Myovant Sciences until it has trouble settling it off, either with new capital or with free cash flow. So, Myovant Sciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Myovant Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Myovant to invest in growth at high rates of return. When we think about Myovant Sciences' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| David Liddy | Eastern Co | 63 | |
| Gene Haning | Rocky Brands | 65 | |
| Tony Adcock | Eastern Co | N/A | |
| Harley Rouda | Rocky Brands | 53 | |
| Zohar Zisapel | Radcom | 75 | |
| Michael McManus | Eastern Co | 75 | |
| Ajita Rajendra | Timken Company | 69 | |
| Arthur Winkleblack | Church Dwight | 63 | |
| Uri Har | Radcom | 80 | |
| Jacqueline Woods | Timken Company | 73 | |
| Kevin Robbins | Mannatech Incorporated | N/A | |
| Robert Shearer | Church Dwight | 69 | |
| Frank Sullivan | Timken Company | 60 | |
| Penry Price | Church Dwight | 52 | |
| Donald Tuttle | Eastern Co | 64 | |
| Curtis Loveland | Rocky Brands | 67 | |
| Larry Jobe | Mannatech Incorporated | 74 | |
| Charles Henry | Eastern Co | 68 | |
| G Haning | Rocky Brands | 65 | |
| Robert Moore | Rocky Brands | 66 | |
| Robert Toth | Mannatech Incorporated | 61 | |
Management Performance
| Return On Asset | -0.18 |
Myovant Sciences Leadership Team
Elected by the shareholders, the Myovant Sciences' board of directors comprises two types of representatives: Myovant Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Myovant. The board's role is to monitor Myovant Sciences' management team and ensure that shareholders' interests are well served. Myovant Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Myovant Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frank Karbe, Principal Financial and Accounting Officer, President and Chief Financial Officer of Myovant Sciences, Inc. | ||
| Juan Ferreira, Chief Commercial Officer - Myovant Sciences, Inc | ||
| Mark Altmeyer, Independent Director | ||
| Nancy Valente, Director | ||
| Kim Sablich, Chief Commercial Officer | ||
| Adele Gulfo, Director, Interim Chief Commercial Officer | ||
| Myrtle Potter, Chairman of the Board | ||
| Terrie Curran, Independent Director | ||
| Lauren Merendino, Chief Commercial Officer | ||
| Keith Manchester, Director | ||
| Marianne Romeo, Head, Global Transactions & Risk Management | ||
| Ann Tomlin, VP HR | ||
| Juan MD, Chief Officer | ||
| Uneek Mehra, Chief Financial and Business Officer, Principal Financial and Accounting Officer | ||
| Frank Torti, Director | ||
| Andria MD, Head Pharmacovigilance | ||
| Matthew JD, Gen Sec | ||
| Vivek Ramaswamy, Director | ||
| Jeffrey Nornhold, Senior Vice President Pharmaceutical Operations & Development | ||
| Albert Liao, Director Communications | ||
| Wayne DeVeydt, Independent Director | ||
| Matthew Lang, General Counsel, Corporate Secretary and Chief Legal and Administrative Officer and Corporate Secretary of Myovant Sciences, Inc. | ||
| Kathleen Sebelius, Lead Independent Director | ||
| Mark Guinan, Independent Director | ||
| David Marek, Principal Executive Officer, Director | ||
| Hiroshi Nomura, Director | ||
| Bryan Selby, VP Devel | ||
| Lynn Seely, Principal Executive Officer, Director |
Myovant Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Myovant Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.18 | |||
| Profit Margin | (0.48) % | |||
| Operating Margin | (0.39) % | |||
| Current Valuation | 2.6 B | |||
| Shares Outstanding | 97.26 M | |||
| Shares Owned By Insiders | 48.61 % | |||
| Shares Owned By Institutions | 56.21 % | |||
| Number Of Shares Shorted | 8.39 M | |||
| Price To Earning | (8.56) X | |||
| Price To Book | 70.01 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Myovant Sciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Myovant Sciences' short interest history, or implied volatility extrapolated from Myovant Sciences options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Other Consideration for investing in Myovant Stock
If you are still planning to invest in Myovant Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Myovant Sciences' history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |